Cargando…

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

BACKGROUND: Ipilimumab improves overall survival in a subset of patients with metastatic melanoma. Peripheral blood T cell receptor (TCR) repertoire diversity has been associated with favorable outcomes in patients with cancer, but its relevance as a biomarker for ipilimumab outcomes remains unknown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Postow, Michael A., Manuel, Manuarii, Wong, Phillip, Yuan, Jianda, Dong, Zhiwan, Liu, Cailian, Perez, Solène, Tanneau, Isabelle, Noel, Marlène, Courtier, Anaïs, Pasqual, Nicolas, Wolchok, Jedd D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469400/ https://www.ncbi.nlm.nih.gov/pubmed/26085931 http://dx.doi.org/10.1186/s40425-015-0070-4

Ejemplares similares

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

ImmunTraCkeR(®) as a reliable TCR repertoire profiling tool to understand immune response and to explore immunotherapy biomarkers
por: Tanneau, Isabelle, et al.
Publicado: (2013)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
por: Ku, Geoffrey Y, et al.
Publicado: (2010)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi)
por: Page, David B, et al.
Publicado: (2014)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients
por: Manuel, Manuarii, et al.
Publicado: (2012)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
por: Friedman, Claire F, et al.
Publicado: (2022)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
por: Montes, Vera, et al.
Publicado: (2018)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
por: Chu, Michael P., et al.
Publicado: (2020)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
por: Chapman, Paul B., et al.
Publicado: (2023)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
por: Anderson, Erik S., et al.
Publicado: (2017)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_q9hto411rce1ac1qp1ku43ttog